Survival and pleurodesis outcome in patients with malignant pleural effusion – a systematic review

Hassan, Maged; Harriss, Elinor; Mercer, Rachel; Rahman, Najib M.

doi:10.1515/pp-2020-0147

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our result, the report of a recently published systematic review by Hassan et al ( 27 ) demonstrated a survival difference according to pleurodesis outcomes in patients with MPE. Additionally, the type of malignancy and respective oncological treatment have been shown to be associated with survival and even pleurodesis outcomes.…”

Section: Discussionsupporting

confidence: 93%

Comparison of outcomes of surgical and other invasive treatment modalities for malignant pleural effusion in patients with pleural carcinomatosis

Schramm,

Eslauer,

Hammoudeh

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

Background Treatment modalities for malignant pleural effusion (MPE) are diverse. The objectives were to analyze actual clinical data from patients with MPE and pleural carcinomatosis and to compare the outcomes of different treatment modalities with regard to effectiveness, survival, morbidity, and mortality as well as the duration of hospitalization. Methods Patients with pathologically proven pleural carcinomatosis or MPE from 2018 to 2020 were included in this retrospective-observational study with additional questionnaires. We identified four treatment modalities: (I) video-assisted thoracic surgery with pleurodesis (VATS, mechanical/chemical); (II) VATS with pleurodesis combined with indwelling pleural catheter (IPC) placement; (III) VATS (without pleurodesis) combined with IPC placement; and (IV) management with IPC placement alone. Results We enrolled 91 patients aged 38–90 years who were treated by either VATS-pleurodesis (N=22), VATS-IPC placement (N=21), a combination of VATS with pleurodesis and IPC placement (N=22), or IPC placement alone (N=26). The mean survival time was 138.3 days. No significant differences were detected among treatment groups regarding the outcome of pleurodesis failure, either initially or later. Patients in the VATS-pleurodesis with IPC group experienced significantly more complications than those in the other treatment modality groups [odds ratio (OR): 3.288, P=0.026]. However, no statistically significant differences were observed regarding the type of adverse event and survival. Hypoalbuminemia, systemic therapy, and successful pleurodesis (P=0.008; P=0.011; P=0.044, respectively) were significantly correlated with survival. In multiple linear regression, hypoalbuminemia persisted as an independent predictor of survival (P=0.031). The type of intervention showed significant differences regarding the duration of hospitalization (P=0.017). IPC placement alone shortened the mean total hospitalization time by 7.9, 5.9, and 7.0 days compared to VATS-pleurodesis (P≤0.001), VATS-IPC placement (P=0.004), and VATS-pleurodesis with IPC placement (P≤0.001), respectively. Conclusions The survival time was very short, and each treatment group had pros and cons. Therefore, decisions should be made on a case-by-case basis. The use of an IPC, even if the lung is not trapped, can significantly reduce the length of hospital stay. VATS is needed when histology is needed. The ideal method for treating recurrent MPE should be simple, effective, and inexpensive, with minimal disturbance to the patient.

show abstract

Section: Discussionsupporting

confidence: 93%

Comparison of outcomes of surgical and other invasive treatment modalities for malignant pleural effusion in patients with pleural carcinomatosis

Schramm,

Eslauer,

Hammoudeh

et al. 2024

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…More recently, a systematic review of survival outcomes in patients with MPE who underwent successful pleurodesis reported that 13 of 15 studies demonstrated improved survival in favor of successful pleurodesis. 12 A similar observation also was made in a study that examined outcomes exclusively in MPM. 13 The authors of the article raise two possibilities for the apparent survival benefit seen in patients who achieve pleurodesis.…”

supporting

confidence: 61%

Malignant Pleural Effusion in Malignant Pleural Mesothelioma

Muruganandan

Duong

2021

Chest

View full text Add to dashboard Cite

“…Finally, it is important to mention that the main benefit of pleurodesis lies in improving the survival of well-selected patients in whom the procedure is successful [157][158][159][160].…”

Section: Benefit Of Pleurodesismentioning

confidence: 99%